Last updated: February 20, 2026
What is NDC 51672-1289?
NDC 51672-1289 corresponds to Ublituximab, a monoclonal antibody developed by TG Therapeutics. It is designed for the treatment of multiple sclerosis (MS) and other autoimmune diseases. The drug received FDA approval in December 2022 for relapsing forms of MS.
Market Landscape
Key Competitors
| Product Name |
Indication |
Approval Date |
Sales (2022) |
Market Share (Estimated) |
| Ocrevus (Ocrelizumab) |
Multiple Sclerosis |
2017 |
$4.16B |
30% |
| Mavenclad (Cladribine) |
Multiple Sclerosis |
2019 |
$950M |
10% |
| Kesimpta (Ofatumumab) |
Multiple Sclerosis |
2020 |
$880M |
8% |
Note: Ublituximab is anticipated to compete primarily with Ocrevus given similar indications and mechanism.
Market Penetration
- The MS therapeutic market approached $14B globally in 2022.
- Monoclonal antibodies dominate MS treatment, capturing approximately 60-70% of prescriptions.
- Ublituximab's approval positions it for rapid entry, aided by existing infrastructure for similar drugs.
Pricing Dynamics
- Current MS monoclonal antibody therapies are priced between $70,000 and $90,000 annually.
- Ocrevus holds an average wholesale price (AWP) of approximately $77,000 per year.
- Discounting, rebates, and insurance coverage significantly influence net prices.
Price Projections
2023–2027 Outlook
| Year |
Estimated Wholesale Price |
Expected Market Share |
Projected Sales (USD) |
Assumptions |
| 2023 |
$75,000 |
2% |
$150M |
Launch phase, initial uptake limited |
| 2024 |
$74,000 |
5% |
$370M |
Expanded prescriber base, insurance coverage |
| 2025 |
$73,000 |
8% |
$740M |
Increased market acceptance |
| 2026 |
$72,000 |
12% |
$1.2B |
Growing physician familiarity |
| 2027 |
$71,000 |
15% |
$1.5B |
Established position in MS segment |
Revenue Assumptions
- Ublituximab’s market share growth relies on successful clinical positioning, post-approval data, and pricing strategies.
- Competitive pricing pressures could drive prices below the assumed levels.
- Insurance reimbursement policies may influence net revenue.
Regulatory and Reimbursement Factors
- FDA approval in December 2022 encourages market entry.
- CMS and private payers have historically negotiated rebates and discounts on MS drugs.
- Likelihood of inclusion in formulary lists should accelerate uptake.
Risks
- Slow market adoption due to competitive landscape.
- Potential label expansions limited by clinical trial data.
- Pricing pressures from existing therapies and biosimilars.
Key Takeaways
- Ublituximab enters a market dominated by established monoclonal antibodies with high revenue and prescriber loyalty.
- Early sales are expected near $150M in 2023, rising to $1.5B by 2027.
- Pricing aligns with current MS monoclonal therapies, with potential for discounts based on payer negotiations.
- Market share growth depends on clinical performance, safety profile, and reimbursement success.
FAQs
1. What factors influence Ublituximab's market share growth?
Clinical efficacy, safety profile, payer reimbursement, physician adoption, and competitive pricing.
2. How does Ublituximab compare to existing MS therapies?
It offers a similar mechanism with potential advantages in dosing schedule, but it must demonstrate superior or equivalent efficacy and safety to secure market share.
3. What is the expected timeline for revenue ramp-up?
Sales could reach $370M in 2024, with substantial growth through 2027 assuming successful adoption.
4. How might biosimilar competition impact prices?
Biosimilars for monoclonal antibodies are emerging and could lead to price concessions, reducing revenue potential.
5. What are regulatory risks?
Any safety concerns or delayed post-market data could affect market acceptance and reimbursement.
Sources
[1] IQVIA. (2022). Global MS Market Report.
[2] FDA. (2022). Ublituximab approval announcement.
[3] Generic Pharma Insights. (2023). MS Monoclonal Antibody Pricing Trends.
[4] CMS. (2022). Medicare Fee Schedule and Rebate Policies.
[5] Statista. (2023). Multiple Sclerosis Treatment Market Revenue.
